EZH2 Promotes Multiple Myeloma Progression via STAT3 Pathway Activation

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Multiple myeloma (MM) is a bone marrow malignancy characterized by clonal plasma cell proliferation.
• The enhancer of zeste homolog 2 (EZH2) and signal transducers and activators of transcription 3 (STAT3) pathway are implicated in various malignancies.

Purpose of the Study:

• To investigate the role of EZH2 in multiple myeloma (MM) progression.
• To elucidate the involvement of the STAT3 signaling pathway in EZH2-mediated MM pathogenesis.
• To identify potential therapeutic targets for MM.

Main Methods:

• Quantitative real-time PCR and western blot to assess EZH2 expression in MM cell lines.
• In vitro manipulation of EZH2 and STAT3 activation using transfection, colivelin, and stattic.
• Functional assays including colony formation, transwell migration, and flow cytometry to evaluate cell proliferation, migration, and apoptosis.

Main Results:

• EZH2 was significantly overexpressed in multiple MM cell lines at both mRNA and protein levels.
• Increased EZH2 expression enhanced MM cell proliferation and migration while inhibiting apoptosis.
• These effects were reversed by STAT3 inhibition and mimicked by STAT3 activation, indicating EZH2 acts via the STAT3 pathway.

Conclusions:

• EZH2 promotes multiple myeloma progression by activating the STAT3 pathway.
• Both EZH2 and STAT3 pathways represent promising therapeutic targets for multiple myeloma treatment.